Christine Desmedt: RECIST criteria need to be reevaluated for that purpose in metastatic setting

Christine Desmedt, Head Laboratory for Translational Breast Cancer Research, KU Leuven, shared a post on X:

“Our systematic review on the documentation of lobular breast cancer #ILC in clinical trials is out today.

We reviewed publications from 93 phase III/IV clinical trials for novel breast cancer treatments.

Key messages:
1 Eligibility restrictions on tumor measurability (very relevant for patients with metastatic #ILC) present in 42% of the trials.
2 Inclusion rates for ILC were documented in 13/93 manuscripts.
3 only 3/13 manuscripts had ILC sub-analyses.
4 No central pathology for ILC was reported while it has been reported that concordance between local and central pathology can be suboptimal.

Urgent and collective efforts are needed to include patients with ILC in clinical trials (RECIST criteria need to be reevaluated for that purpose in metastatic setting) and to better document and plan subanalyses on ILC. The patients deserve it.

This was a great effort by Karen Van Baelen, Josephine Van Cauwenberge, Patrick WB Derksen, Anne Vincent-Salomon, ELBCC, with many patients advocates: Lobular Breast Cancer IRL, LobularBCUK, Julia Katherine, Laurie Hutcheson, Tone Lien, and many others.

This work is dedicated to Leigh Pate and Deborah Mueller, two patient advocates who are greatly missed”

Source: Christine Desmedt/X